Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 23Lymphoma, Mantle-Cell 15Lymphoma, Follicular 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Myeloid, Acute 10Waldenstrom Macroglobulinemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Carcinoma, Non-Small-Cell Lung 8Unspecified Adult Solid Tumor, Protocol Specific 7Neoplasms, Plasma Cell 7Lymphoma 7Neoplasms 6Hodgkin Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Congenital Abnormalities 4Burkitt Lymphoma 4Sezary Syndrome 3Recurrence 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

Paclitaxel 11Carboplatin 9Taxes 8Gefitinib 7Radiotherapy 5Bevacizumab 5Radiation 4Erlotinib Hydrochloride 4Cisplatin 4Gemcitabine 3Etoposide 3Docetaxel 3Radiotherapy, Conformal 2Neoadjuvant Therapy 2veliparib 1vandetanib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1motesanib diphosphate 1Thalidomide 1TER 286 1Specimen Handling 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1MK 2206 1Ipilimumab 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma, Bronchiolo-Alveolar × Bortezomib × Clear all
NCT00118144 2014-08-21

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 7 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡